ReviewAnnals of laboratory medicine2024
The Use of Bone-Turnover Markers in Asia-Pacific Populations.
Review in Annals of laboratory medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Evaluating combined acupuncture and antiresorptive therapy in Chinese women with postmenopausal osteoporosis: a systematic review and network meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Bone Turnover Markers, DXA and Mineral Metabolism in Long-Term Kidney Transplant Recipients: A Cross-Sectional Comparative Study.Journal of clinical medicine · 2026Article
- Article
- Current practice and barriers in fragility hip fracture management: insights from a national survey of Thai orthopaedic surgeons.BMC health services research · 2026Article
- Time-Dependent Effect of Anti-seizure Medications on Bone Metabolism in Patients with Epilepsy: A Cross-Sectional Study.Neurology and therapy · 2026Article
- Exploring Women's Knowledge of Nutrition and Bone Health: A Preventive Focus on Osteoporosis.Cureus · 2025Article
- Development and evaluation of a machine learning model for osteoporosis risk prediction in Korean women.BMC women's health · 2025Article
- Association between fibrinogen-to-albumin ratio and bone metabolism markers (β-CTX and P1NP) in Chinese individuals with osteoporotic fracture: a cross-sectional investigation.BMC musculoskeletal disorders · 2025Observational
- Article
- An acid-responsive bone-targeting nanoplatform loaded with curcumin balances osteogenic and osteoclastic functions.Regenerative biomaterials · 2025Article
- Effects of dietary supplements on bone turnover markers in women after menopause: a network meta-analysis.PeerJ · 2025Article
- Relationship between bone turnover markers and diabetic kidney disease in patients with type 2 diabetes.Frontiers in endocrinology · 2025Article
- An Overview on the Big Players in Bone Tissue Engineering: Biomaterials, Scaffolds and Cells.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone-turnover marker (BTM) measurements in the blood or urine reflect the bone-remodeling rate and may be useful for studying and clinically managing metabolic bone diseases. Substantial evidence supporting the diagnostic use of BTMs has accumulated in recent years, together with the publication of several guidelines. Most clinical trials and observational and reference-interval studies have been performed in the Northern Hemisphere and have mainly involved Caucasian populations. This review focuses on the available data for populations from the Asia-Pacific region and offers guidance for using BTMs as diagnostic biomarkers in these populations. The procollagen I N-terminal propeptide and β-isomerized C-terminal telopeptide of type-I collagen (measured in plasma) are reference BTMs used for investigating osteoporosis in clinical settings. Premenopausal reference intervals (established for use with Asia-Pacific populations) and reference change values and treatment targets (used to monitor osteoporosis treatment) help guide the management of osteoporosis. Measuring BTMs that are not affected by renal failure, such as the bone-specific isoenzyme alkaline phosphatase and tartrate-resistant acid phosphatase 5b, may be advantageous for patients with advanced chronic kidney disease. Further studies of the use of BTMs in individuals with metabolic bone disease, coupled with the harmonization of commercial assays to provide equivalent results, will further enhance their clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.